The post-COVID slump in the pharma industry may be on the outs as mergers and acquisitions activity picks up again, according to a report out of EY this week. Consolidation in the pharma world jumped ...

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune ...

Mergers and acquisitions (M&A) in the pharma and life sciences sectors are expected to see a bit of an upturn in 2025 — even if the value of those transactions remains smaller-to-midsized. PwC’s U.S.

The U.S. antitrust watchdog believes that its current process of reviewing large pharma mergers just doesn’t work. As experts propose heightened scrutiny, at least one analyst is projecting a ...

Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their ...

India’s Sun Pharmaceutical Industries agrees to buy the women’s health company for $14 a share in an all-cash deal.

Rising healthcare consumerization, self-care and cost-containment have opened new opportunities for private equity in pharma, along with large companies in the sector increasingly pursuing ...

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. M Pharmaceutical (CSE:MQ) has agreed to acquire IP associated with temporary controllable pseudobezoars, a ...

Amber Nigam is CEO and cofounder of basys.ai, a Harvard-based company streamlining prior authorization for health plans with generative AI. The pharmaceutical industry is at a significant crossroads, ...